OGT and neoplasm: Most studies report increased protein O-GlcNAcylation and the presence of changes in OGT and/or OGA mRNA and protein expression in prostate, colorectal, pancreatic, breast, ovary, urinary bladder, bile duct, endometrial, lung or liver cancers, where a positive association was disclosed between O-GlcNAc-cycling enzyme expression and a number of clinicopathological variables including higher tumor grade, stage, higher differentiation, enhanced tumor cell proliferation and invasion as well as poor prognosis [11, 14, 20–28].